MedPath

Nebivolol

Generic Name
Nebivolol
Brand Names
Bystolic
Drug Type
Small Molecule
Chemical Formula
C22H25F2NO4
CAS Number
118457-14-0
Unique Ingredient Identifier
030Y90569U
Background

Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than atenolol, propranolol, or pindolol. Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics.

Nebivolol was granted FDA approval on 17 December 2007.

Indication

Nebivolol is indicated to treat hypertension.

Associated Conditions
Hypertension
Associated Therapies
-

Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Metoprolol succinate
Drug: Nebivolol
Procedure: Forearm blood flow
Procedure: Microneurography
Procedure: Rhythmic handgrip exercise
Procedure: Lower body negative pressure
Drug: Angiotensin II
First Posted Date
2012-01-02
Last Posted Date
2020-07-07
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
46
Registration Number
NCT01502787
Locations
🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Metoprolol succinate
Drug: Nebivolol
Procedure: Non-invasive measurement of Cardiac Output (CO)
Procedure: Endothelial cell collection
Procedure: Microvascular perfusion assessment using Definity
First Posted Date
2011-12-30
Last Posted Date
2018-11-06
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
32
Registration Number
NCT01501929
Locations
🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure

Phase 3
Completed
Conditions
Hypertension
Peripheral Artery Disease
Interventions
First Posted Date
2011-12-26
Last Posted Date
2014-12-17
Lead Sponsor
Thomas Jefferson University
Target Recruit Count
17
Registration Number
NCT01499134
Locations
🇺🇸

Thomas Jefferson University, Philadelphia, Pennsylvania, United States

The Impact of Nebivolol Versus Metoprolol on Quality of Life

Not Applicable
Terminated
Conditions
Transplant; Failure, Kidney
Hypertension
Interventions
First Posted Date
2011-09-27
Last Posted Date
2017-04-20
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
11
Registration Number
NCT01441570
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Lahey Clinic, Burlington, Massachusetts, United States

Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Nebivolol
Drug: Placebo
First Posted Date
2011-08-12
Last Posted Date
2013-05-16
Lead Sponsor
Forest Laboratories
Target Recruit Count
641
Registration Number
NCT01415531
Locations
🇺🇸

Forest Investigative Site 011, Raleigh, North Carolina, United States

🇺🇸

Forest Investigative Site 065, Phoenix, Arizona, United States

🇺🇸

Forest Investigative Site 067, Phoenix, Arizona, United States

and more 72 locations

Nebivolol and the Endothelin (ET)-1 System

Phase 4
Completed
Conditions
Prehypertension
Hypertension
Interventions
Drug: Placebo
Drug: Nebivolol
Drug: Metoprolol
Other: Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)
Other: FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)
Other: FBF response to Acetylcholine
Other: FBF response to Sodium Nitroprusside
Other: FBF response to BQ-123+BQ-788+ACh
First Posted Date
2011-07-15
Last Posted Date
2019-01-02
Lead Sponsor
University of Colorado, Boulder
Target Recruit Count
42
Registration Number
NCT01395329
Locations
🇺🇸

UC-Boulder Clinical and Translational Research Center, Boulder, Colorado, United States

Regression of Myocardial Steatosis by Nebivolol

Early Phase 1
Completed
Conditions
Cardiac Steatosis and Lipotoxicity
Interventions
First Posted Date
2011-05-23
Last Posted Date
2017-07-14
Lead Sponsor
Lidia Szczepaniak
Target Recruit Count
31
Registration Number
NCT01358409
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function

Phase 4
Completed
Conditions
Hypertension
Interventions
First Posted Date
2010-11-25
Last Posted Date
2010-11-25
Lead Sponsor
Berlin-Chemie AG Menarini Group
Target Recruit Count
80
Registration Number
NCT01248338
Locations
🇪🇪

Cardiology Clinic of Tartu University Clinics, Tartu, Estonia

Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques

Phase 4
Completed
Conditions
Atherosclerosis
Endothelial Function
Interventions
First Posted Date
2010-10-29
Last Posted Date
2015-02-27
Lead Sponsor
Emory University
Target Recruit Count
29
Registration Number
NCT01230892
Locations
🇺🇸

Emory University Hospital, Atlanta, Georgia, United States

An Advanced Echocardiographic Evaluation of Nebivolol

Phase 4
Terminated
Conditions
Hypertension
Interventions
First Posted Date
2010-09-21
Last Posted Date
2018-02-15
Lead Sponsor
Jack Rubinstein
Target Recruit Count
2
Registration Number
NCT01206439
Locations
🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath